HYPERPARATHYROIDISM AND ERYTHROPOIETIN RESISTANCE IN CKD PATIENTS

Abstract

Anemia is a prevalent complication in patients with chronic kidney disease (CKD) and is particularly common in those with end-stage renal disease (ESRD). This anemia results from a decrease in endogenous erythropoietin production, which is closely linked to the progressive decline in kidney function. To manage anemia in CKD patients, the use of erythropoietin stimulating agents (ESAs), such as epoetin alfa (EPO), is recommended. Current practice involves titrating the ESA dose to achieve and maintain hemoglobin levels within the range recommended by KDIGO guidelines, typically not exceeding 11.5 g/dL.